Antibiotic prophylaxis in the era of multidrug-resistant bacteria

被引:13
|
作者
Wittekamp, Bastiaan H. J. [1 ]
Bonten, Marc J. M. [1 ]
机构
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3584 CX Utrecht, Netherlands
关键词
antibiotic; intensive care; prophylaxis; resistance; selective digestive tract decontamination; selective oropharyngeal decontamination;
D O I
10.1517/13543784.2012.681642
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The prophylactic use of antibiotics can only be justified when clinical benefits on relevant patient outcomes, such as morbidity or mortality, cost-effectiveness, and absence of immediate emergence of antibiotic resistance have been unequivocally demonstrated. In some intensive care unit (ICU) patients, antibiotic prophylaxis is used as part of selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD). Recent trials in ICUs with low levels of antibiotic resistance strongly suggest that both regimens reduce the incidence of ICU-acquired infections and improve patient survival. Naturally, the unique microbial ecology of such settings reduce generalizability of results. Therefore, the routine use of SOD and SDD remains highly controversial, especially in ICUs with higher levels of antibiotic resistance. Moreover, convincing evidence is still missing on several important aspects related to efficacy and safety. Despite numerous trials, effects of SDD and SOD on antibiotic resistance during and after decolonization treatment have still been insufficiently investigated, and existing results are contradicting. Furthermore, the effects of both regimens on the non-culturable part of the intestinal flora remain unknown. Finally, cost-effectiveness has not been thoroughly investigated, and prices of the antimicrobial agents that have been used have increased dramatically in recent years. In this review, important knowledge gaps that so far prevent the widespread use of SDD and SOD will be addressed.
引用
收藏
页码:767 / 772
页数:6
相关论文
共 50 条
  • [31] Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria
    Jean, Shio-Shin
    Hsueh, Shun-Chung
    Lee, Wen-Sen
    Hsueh, Po-Ren
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2019, 17 (05) : 307 - 309
  • [32] Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria
    Ruhnke, Markus
    Arnold, Renate
    Gastmeier, Petra
    LANCET ONCOLOGY, 2014, 15 (13): : E606 - E619
  • [33] Current status of multidrug-resistant bacteria
    Kim, Dokyun
    Jeong, Seok Hoon
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2022, 65 (08): : 468 - 477
  • [34] Multidrug-resistant bacteria in animals and humans
    Koeck, R.
    Cuny, C.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2020, 115 (03) : 189 - 197
  • [35] Concerns about multidrug-resistant bacteria
    不详
    LABORATORY MEDICINE, 2003, 34 (04) : 266 - 266
  • [36] Multidrug-resistant bacteria: what is the threat?
    Bassetti, Matteo
    Righi, Elda
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 428 - 432
  • [37] Multidrug-Resistant Bacteria in a Gynecology Department
    Dahma, George
    Dumitru, Catalin
    Laj, Oana
    Bobia, Ana
    Matica, Silvia Iulia
    Oancea, Dennis
    Nitu, Razvan
    Horhat, Ioana Delia
    PROCEEDINGS OF SOGR 2018: THE 17TH NATIONAL CONGRESS OF THE ROMANIAN SOCIETY OF OBSTETRICS AND GYNECOLOGY & FIRST ADVANCED COLPOSCOPY COURSE, 2019, : 258 - 262
  • [38] Multidrug-Resistant Bacteria in Immunocompromised Patients
    Duhaniuc, Alexandru
    Paduraru, Diana
    Nastase, Eduard-Vasile
    Trofin, Felicia
    Iancu, Luminia-Smaranda
    Sima, Cristina-Mihaela
    Dorneanu, Olivia-Simona
    PHARMACEUTICALS, 2024, 17 (09)
  • [39] Multidrug-resistant bacteria in lung transplantation
    Dominguez, Fernando
    Blodget, Emily
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2020, 25 (04) : 348 - 350
  • [40] Multidrug-Resistant Bacteria in the Community: An Update
    van Duin, David
    Paterson, David L.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2020, 34 (04) : 709 - +